Serina Therapeutics, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
AMEX
Serina Therapeutics has scheduled its 2026 Annual Meeting for June 17, 2026, to address key capital structure, equity incentive, and governance proposals.
AMEX
Serina Therapeutics, Inc. filed an amendment to its definitive proxy statement, clarifying details for a stockholder vote on issuing common stock related to convertible notes and warrants.
AMEX
Serina Therapeutics, Inc. has filed its definitive proxy statement with the U.S. Securities and Exchange Commission.
AMEX
Serina Therapeutics, Inc. is holding its Annual Meeting to elect directors, ratify auditors, and approve a significant common stock issuance tied to a $20 million convertible note and warrants to fund clinical trials.
AMEX
Serina Therapeutics, Inc. has filed a definitive proxy statement with the SEC.
AMEX
Serina Therapeutics is asking stockholders to approve an amendment to its 2024 Equity Incentive Plan to increase the share reserve and introduce an evergreen provision.
AMEX
Serina Therapeutics is asking stockholders to approve an amendment to its 2024 Equity Incentive Plan to increase the share reserve and introduce an evergreen provision.